Company: CRNX
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0000950170-25-057452
Chunk: 0

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

| Filed by the Registrant   | Filed by a Party other than the Registrant   |

Check the appropriate box:

|  |     | Preliminary Proxy Statement                                                     |
|  |     | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|  |     | Definitive Proxy Statement                                                      |
|  |     | Definitive Additional Materials                                                 |
|  |     | Soliciting Material under §240.14a-12                                           |

Crinetics Pharmaceuticals, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply):

|  |     | No fee required                                                                                     |
|  |     | Fee paid previously with preliminary materials                                                      |
|  |     | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |

<div align='center'>i

6055 Lusk Boulevard

San Diego, CA 92121

NOTICE OF ANNUAL MEETING OF

STOCKHOLDERS AND PROXY STATEMENT</div>

Dear Stockholder:

The annual meeting of stockholders of Crinetics Pharmaceuticals, Inc. will be held on June 11, 2025 at 8:00 a.m., Pacific Time via a live webcast, for the following purposes:

to elect three directors to serve as Class I directors for a three-year term to expire at the 2028 annual meeting of stockholders;

to consider and vote upon the ratification of the selection of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2025;

to consider and vote upon, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; and

to transact such other business as may be properly brought before the annual meeting or any adjournment or postponement thereof.

As noted above, our annual